Diagnostic · Vascular
Endothelial biomarkers and flow-mediated dilation
If the vessel lining is injured in long COVID, can we measure it? Tests like flow-mediated dilation and circulating endothelial cell counts probe exactly that, and they show abnormalities, but they remain research tools rather than something that changes a clinic visit today.
Short version: endothelial tests (flow-mediated dilation, circulating endothelial cells) show vessel-lining injury in long COVID, but they are research-grade and not yet validated to guide individual care.
Measuring the vessel lining
Because vessel-lining injury is central to long COVID, tests that probe it are of interest: flow-mediated dilation (an ultrasound of how an artery widens), counts of circulating endothelial cells shed into the blood, and markers of clotting and inflammation.1
What they reveal
Studies report impaired flow-mediated dilation and raised circulating endothelial cells in long COVID, consistent with a damaged, less responsive lining. These are mostly research measures rather than routine clinic tests.1
research-grade
Why it is not yet a clinic test
No single endothelial biomarker is validated to diagnose long COVID or guide its treatment. They strengthen the vascular picture and drive research, but a normal or abnormal result does not yet change individual care.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- Whether any endothelial marker can diagnose long COVID.
- Whether they predict who recovers.
- How to standardize the measurements.
- Whether they can guide vascular treatment.
References
Every reference is free to read in full.